
BBC News is saying that Semaglutide, better known as Ozempic, "has far-reaching benefits beyond what we initially imagined," Prof Harlan Krumholz, from the Yale School of Medicine, said following the publication of several new studies.
Semaglutide is the active ingredient in medicines like Ozempic, Wegovy, and Rybelsus and it is already taken by millions around the world for weight loss in specific patients, and also to lower blood sugar levels, and to reduce the risk of major cardiovascular events such as heart attack or stroke in certain patients. Semaglutide is a GLP-1 agonist that works by increasing insulin release, lowering the amount of glucagon released, delaying gastric emptying, and reducing appetite.

The researchers found that the drug could be used to treat a wide range of illnesses linked to heart failure, arthritis, Alzheimer's and even cancer, and it also reduces inflammation. The new data has been published in a number of medical journals, including the Journal of the American College of Cardiology (JACC), which Prof Krumholz edits.